Prospective Clinical Trial Registration  by Williams, Hywel C. & Stern, Robert S.
Prospective Clinical Trial Registration
Hywel C. Williams and Robert S. Sternw
Centre of Evidence-Based Dermatology, Queen’s Medical Centre University Hospital NHS Trust, Nottingham, UK; wBeth Israel Deaconess Medical Center,
Department of Dermatology, Harvard Medical School, Boston, Massachusetts, USA
What Exactly Have the ICMJE Proposed?
The International Committee of Medical Journal Editors
(ICMJE) is a group of the world’s leading medical journals
whose participants meet annually to improve standards in
manuscripts submitted to biomedical journals. In Septem-
ber 2004, the ICMJE announced a tough new stance on
registering clinical trials. All trials that start enrolling partic-
ipants after July 1, 2005 must register their trial in a suitable
publicly accessible register before that date in order to be
considered for subsequent publication in those journals.
Those trials that have started enrolment before July 1, 2005
must register before September 13, 2005 to be considered
for publication (De Angelis et al, 2004). The Journal of In-
vestigative Dermatology subscribes to these standards.
Why Is Prospective Trial Registration
Such a Big Issue?
The ICMJE points out that researchers have an obligation
to conduct themselves ethically and to report their results
honestly. Honest reporting begins with revealing the exist-
ence of all clinical studies, even those that reflect unfavor-
ably on a research sponsor’s product or hypothesis.
Publication bias classically refers to selective publication
of studies with favorable results. For example, in 2003, Me-
lander et al (2003) traced the fate of 42 placebo-controlled
studies of five selective serotonin reuptake inhibitors sub-
mitted to the Swedish drug regulatory authority as a basis
for marketing approval for treating major depression, and
compared these with the studies actually published be-
tween 1983 and 1999. The 42 trials are depicted in Fig 1,
with the red circles representing studies showing ‘‘positive’’
results, and the blue circles representing studies with non-
significant results. The Figure shows how the studies with
‘‘positive’’ results were published as stand-alone publica-
tions (shown as green diamonds in the figure) much more
often than studies with non-significant results. The figure
also shows that studies with positive results were included
more often in meta-analyses (yellow squares) than the non-
significant studies. What little research is available in the
world of dermatological clinical trials suggests that it is not
immune to such practices. For example, a UK Government-
funded meta-analysis of evening primrose oil for atopic
dermatitis included 20 trials, eight of which remain unpub-
lished in the public domain (Williams, 2003). Duplicate pub-
lication is another way to emphasize the result of studies
that sponsors find most to their liking. For example, one
systematic review of 278 trials of atopic dermatitis treat-
ments found eight duplicate publications (i.e., the same
clinical trial data from one trial presented in two separate
journals) and one triplicate publication (Hoare et al, 2000).
Some sponsors have applied substantial pressures to sup-
press or delay the publication of meritorious studies, whose
results were not favorable to their product (Rennie, 1997).
A prospective register of trials would not guarantee that all
trials are eventually published, but it would at least guide
research users on what studies have been carried out
so that questions can be asked if those studies have not
been published.
A further advantage of registering the basic details of
a clinical trial beforehand is to minimize selective emphasis
of positive post hoc subgroup analysis—in other words,
the practice of emphasizing some minor secondary and
statistically significant change in disease score in the ab-
stract and conclusion, when in fact the primary outcome
analysis was non-significant (Diepgen, 2002). For example,
an article titled ‘‘A randomized investigator—blinded study
comparing pimecrolimus 1% with tacrolimus ointment
0.03% in the treatment of pediatric patients with moderate
atopic dermatitis’’ barely discussed relative efficacy, but in-
stead emphasized ease of application (Kempers et al,
2004). Had this trial been registered, the editors (and hope-
fully the readers) could have determined whether the paper
represented post hoc analysis or was merely titled in a
somewhat peculiar manner for a study focused on which
drug is nicer to apply.
Some study results have broad appeal and sufficient
merit for publication in high-impact general medical journals
(Stern, 2003). Yet, one wonders whether the publication of
two similar phase three trials of efalizumab for psoriasis
within weeks of each other in JAMA and the NEJM by the
same overall group funded by the same company without
acknowledging each other came very close to the spirit of
duplicate publication (Gordon et al, 2003; Lebwohl et al,
2003). A clinical trial registry would help address the prob-
lem if the sponsor of an intervention were required to reveal
to the editors the status of any works conducted by the
same study group submitted for publication for all clinical
studies they sponsor.
Another reason for registering all ongoing clinical trials is
simply to avoid unnecessary duplication of efforts. Thus, it
should be incumbent upon any trialist to check that their
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study is not being carried out elsewhere in the world before
potentially wasting their time as well that of their patients
and sponsors in carrying out the same work.
Where Should You Register Your Trial?
The Journal of Investigative Dermatology does not wish to
be too prescriptive with regard to which register its readers
submit their trials to, providing the register fulfills the re-
quirements set out in Fig 2. The ICMJE has suggested
www.clinicaltrials.gov as its preferred register, a registry
sponsored by the US National Library of Medicine. The
register is free to use, and it contains comprehensive data
on registered trials that are extracted from sponsors and
lead investigators using a 12-page form. Although the reg-
ister would be the automatic home for new investigational
drug applications to the US Food and Drug Administration,
it is unclear whether non-drug, non-NIH trials from low- to
middle-income countries can be registered (Abbasi, 2004).
Another registry worth considering is the International
Standard Randomised Controlled Trial Number (ISRCTN)
registry (www.controlled-trials.com), managed by a com-
mercial company called Controlled Clinical Trials. Although
access to the registry is free, registration for trials that do
not emanate from developing countries carries a $144
(h117) charge, which might be a disincentive to some. Other
mechanisms to register trials that fulfill the JID registry cri-
teria exist. One example unique to dermatology is the Co-
chrane Skin Group prospective trials register http://www.
nottingham.ac.uk/muzd/about/ongoingtrials. The Coch-
rane Skin Group editorial base is supported by public funds
and supports an international and largely voluntary com-
munity dedicated to preparing and maintaining systematic
reviews of interventions for skin diseases (Williams et al,
1998). The Cochrane Skin Group has been running its reg-
istry of prospective trials for the international dermatology
community for the last 2 years and encourages the regis-
tration of completed but unpublished studies, as well as
ongoing and planned clinical trials. Complete registration of
trials will facilitate comprehensive systematic reviews by
helping to identify all relevant trials. The one-page registra-
tion form for the Cochrane Skin Group trials register takes
about 5 minutes to complete, and registration is free of
charge. The emphasis on free registration and minimal pa-
perwork might be important in order to avoid selective
publication that might occur if those trials that lacked direct
financial support were discouraged from registering.
What Type of Study Should Be Registered?
The ICMJE defines a clinical trial as any research project
that prospectively assigns human subjects to intervention or
comparison groups to study the cause-and-effect relation-
ship between a medical intervention and a health outcome.
In other words, the register is not confined to drug studies
and can include randomized controlled trials of medical
devices, a new surgical technique, or even a new way of
organizing care such as nurse-led clinics. Studies designed
for other purposes, such as to study pharmacokinetics,
cellular mechanisms in isolation or major toxicity (e.g.,
phase I trials), would be exempt.
The Bottom Line
Many a stern word has been aired on the general poor
reporting standards of dermatological trials (Bigby et al,
1985), but little seems to have changed over the last 20
years (Adetugbo and Williams, 2000; Naldi et al, 2003). It is
easy to accept publication bias as ‘‘just the way things are’’;
Figure 1
An illustration of publication bias. Selective publication of ‘‘positive’’
studies of five selective serotonin reuptake inhibitors submitted to the
Swedish drug regulatory authority as a basis for marketing approval for
treating major depression (Reproduced with the kind permission of the
BMJ Publishing Group from Melander et al, 2003).
The Journal of Investigative Dermatology recommendations for a suitable 
trial registry include: 
• Free public access 
• Each trial has a unique identifier 
• Registered information is checked 
• Registered entry contains trial name, lead investigator, 
methodology, interventions, primary outcomes, sponsor and status 
• (Desirable) No charge to register trials and easy to complete 
Figure2
Traits of a suitable clinical trial registry.
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yet the effect of selective reporting of evidence is a major
disservice to the trust and altruism at the heart of patients
volunteering to participate in dermatological clinical trials.
Selective reporting distorts the true effects of medical in-
terventions, leading to a waste of doctors’ and patients’
time, a waste of public money, and possible serious harms
(Chalmers, 2004). It is our vision that the data from all der-
matological clinical trials conducted on volunteers belong to
the people. Registering your clinical trial, searching the reg-
istries for other trials that evaluate similar interventions, and
sharing this information with editors and readers bring us
one step closer to such a vision.
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